Cutler Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Cutler Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,100	Closed	-$18K	–	5835
2022 Q2	$18K	Buy	+1,100	New	+$48.9K	﹤0.01%	2779
2022 Q1	–	Sell	-900	Closed	-$20K	–	6395
2021 Q4	$20K	Buy	+900	New	+$40.2K	﹤0.01%	3144
2021 Q1	–	Sell	-300	Closed	-$6K	–	6567
2020 Q4	$6K	Buy	+300	New	+$32.9K	﹤0.01%	3589

Cutler Group's TPTX Position: Q3 2022 in Review

Cutler Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,200 shares — an estimated $90K sold.

Cutler Group first reported a position in TPTX in Q3 2019 and held it in 8 quarters. The position peaked at $163K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Cutler Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Cutler Group sold 1,200 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $90K.
Cutler Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
Cutler Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $163K in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.